Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04082351|
Recruitment Status : Completed
First Posted : September 9, 2019
Last Update Posted : September 10, 2019
|Condition or disease||Intervention/treatment||Phase|
|Type2 Diabetes||Dietary Supplement: Nanotechnology structured water ( Magnalife) Dietary Supplement: ordinary water||Not Applicable|
This is a blind randomized control trial, according to CONSORT guidelines for randomization, "Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups.", that included 387 patients with Type 2 diabetes mellitus in Diabetes Care Center, Sulaymaniyah, Kurdistan region from July 2016 till February 2018. A total of 387 patients with type 2 diabetes who were patients in this center and agreed to participate in this clinical trial were included in this study.
In group A, patients were given nanotechnology structured water Magnalife® and in group B they were given ordinary bottled drinking water as a control . The bottles were unlabeled so that the patients did not know which water they were drinking. Then they were asked to eat their usual food and to drink their usual drinks, also they could drink water ad libitum after drinking the daily doses, and to have the same physical activities that they used to do in their usual daily life. They were instructed to take their medications as usual, and were told to come to test their blood sugar level at the end of the third month to get the HbA1c tested at the end of the three months of drinking the water.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||387 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Evaluation of Using a Nanotechnology Structured Water Magnalife® to Achieve Controlled Blood Glucose Level in Type 2 Diabetic Patients.|
|Actual Study Start Date :||July 3, 2016|
|Actual Primary Completion Date :||February 16, 2018|
|Actual Study Completion Date :||February 16, 2018|
Active Comparator: Magnalife
the group of patients receiving the nanotechnology structured water
Dietary Supplement: Nanotechnology structured water ( Magnalife)
Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
Other Name: Magnalife
Placebo Comparator: Ordinary water
the group of patients receiving ordinary water
Dietary Supplement: ordinary water
Ordinary bottled water
Other Name: Bottled drinking water
- HbA1c [ Time Frame: three months ]measurement of HbA1c
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04082351
|Principal Investigator:||Ali K M.Sami, Ph.D.||College of Medicine, University of Sulaimani|